LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Gilead Sciences Inc.

Gilead Sciences Inc.

Fermé

SecteurSoins de santé

134.43 2.87

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

133.71

Max

134.46

Chiffres clés
By Trading Economics
Revenu	-162M 2B
Ventes	-965M 7B
P/E Moyenne du Secteur	17.642 49.701
BPA	2.03
Rendement du dividende	2.46
Marge bénéficiaire	29.037
Employés	17,000
EBITDA	18M 2.4B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+18.96% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	2.46% 2.39%
Prochains Résultats	6 août 2026
Date du Prochain Dividende	29 juin 2026
Date du Prochain Détachement de Dividende	15 juin 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-3.7B 161B
Ouverture précédente	131.56
Clôture précédente	134.43

Sentiment de l'Actualité

By Acuity

33%

67%

76 / 345 Classement par Healthcare

Gilead Sciences Inc. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 mai 2026, 20:49 UTC

Résultats

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7 avr. 2026, 14:24 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7 avr. 2026, 12:53 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

8 mai 2026, 08:10 UTC

Résultats

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8 mai 2026, 08:08 UTC

Résultats

Acquisitions, Fusions, Rachats

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:33 UTC

Résultats

Acquisitions, Fusions, Rachats

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 21:09 UTC

Résultats

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mai 2026, 20:51 UTC

Résultats

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mai 2026, 20:06 UTC

Résultats

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7 mai 2026, 20:05 UTC

Résultats

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7 mai 2026, 20:05 UTC

Résultats

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7 mai 2026, 20:02 UTC

Résultats

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7 mai 2026, 20:01 UTC

Résultats

Gilead Sciences 1Q Rev $6.96B >GILD

7 mai 2026, 20:01 UTC

Résultats

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7 mai 2026, 20:01 UTC

Résultats

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7 mai 2026, 20:01 UTC

Résultats

Gilead Sciences 1Q EPS $1.61 >GILD

28 avr. 2026, 12:45 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17 avr. 2026, 12:32 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17 avr. 2026, 12:30 UTC

Acquisitions, Fusions, Rachats

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7 avr. 2026, 14:36 UTC

Acquisitions, Fusions, Rachats

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7 avr. 2026, 14:35 UTC

Acquisitions, Fusions, Rachats

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7 avr. 2026, 14:34 UTC

Acquisitions, Fusions, Rachats

EQT Life Sciences: Gilead Will Also Buy TUB-030

7 avr. 2026, 14:28 UTC

Acquisitions, Fusions, Rachats

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7 avr. 2026, 14:23 UTC

Market Talk

Acquisitions, Fusions, Rachats

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7 avr. 2026, 13:55 UTC

Market Talk

Acquisitions, Fusions, Rachats

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7 avr. 2026, 13:14 UTC

Acquisitions, Fusions, Rachats

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7 avr. 2026, 12:30 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7 avr. 2026, 12:30 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7 avr. 2026, 12:30 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

7 avr. 2026, 12:30 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Tubulis Deal Includes $3.15B Upfront Cash Consideration on Cash-Free, Debt-Free Basis >GILD

Comparaison

Variation de prix

Gilead Sciences Inc. prévision

Objectif de Prix

By TipRanks

18.96% hausse

Prévisions sur 12 Mois

Moyen 159.84 USD 18.96%

Haut 180 USD

Bas 122 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

21 ratings

Achat

Maintien

Vente

Basé sur 21 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

76 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.